B 006
Alternative Names: Anti-CD30 monoclonal antibody-MCC-DM1 conjugate; anti-CD30-MCC-DM1; B006; Recombinant anti-CD30 humanised monoclonal antibody conjugateLatest Information Update: 26 Apr 2022
At a glance
- Originator Shanghai Pharmaceuticals Holding
- Class Antineoplastics; Drug conjugates; Immunotoxins; Maytansinoids; Monoclonal antibodies
- Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Anaplastic large cell lymphoma; Hodgkin's disease
- Preclinical Cutaneous T-cell lymphoma
Most Recent Events
- 30 Mar 2022 Shanghai Pharmaceuticals has independent intellectual property rights for B 006
- 30 Mar 2022 Phase-I clinical trials in Anaplastic large cell lymphoma in China (Parenteral), before March 2022
- 30 Mar 2022 Phase-I clinical trials in Hodgkin's disease in China (Parenteral), before March 2022